Evidence-based management of nutrigenomics expectations and ELSIs

Pharmacogenomics

Volumn 8, Issue 8, 2007, Pages 1051-1062

  Ozdemir, Vural ^a   Godard, Béatrice ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Diet gene interaction; ELSIs; Ethical legal social issues; Nutrigenomics; Qualitative research; Research ethics; Social pharmacology; Sociology of innovation; Sociotechnical expectations

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); APOLIPOPROTEIN E4; ASTAXANTHIN; HOMOCYSTEINE;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; DIET SUPPLEMENTATION; DIETARY INTAKE; EMPLOYMENT; EPIGENETICS; EVIDENCE BASED MEDICINE; FOOD COMPOSITION; GENE EXPRESSION REGULATION; GENE INTERACTION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEALTH INSURANCE; HUMAN; LEGAL ASPECT; MEDICAL ETHICS; NONHUMAN; NUTRIGENOMICS; OXIDATIVE STRESS; PHARMACOGENOMICS; PHENOTYPE; PREVENTIVE MEDICINE; PROFESSIONAL SECRECY; PUBLIC HEALTH; QUALITATIVE RESEARCH; RISK FACTOR; SOCIAL PSYCHOLOGY; SYSTEMS BIOLOGY;

ANIMALS; DIET; EVIDENCE-BASED MEDICINE; GENOME, HUMAN; HUMANS; NUTRIGENOMICS; NUTRITION PHYSIOLOGY;

EID: 34548718253     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.8.1051     Document Type: Article

References (74)

1. Brown N, Rappert B, Webster A: Contested Futures: A Sociology of Prospective Techno-science. Ashgate Publishing, Aldershot, UK (2000).
2. Selin C: Expectations and the emergence of nanotechnology. Sci. Technol. Human Values 32, 196-220 (2007).
3. Hedgecoe AM: Terminology and the construction of scientific disciplines: the case of pharmacogenomics. Sci. Technol. Human Values 28, 513-537 (2003).
4. Gripeos D: The silent proliferation of virtual reality: unpacking the video game industry. Presented at: Annual Meeting of the Society for Social Studies of Science and Technology (4S), Vancouver, BC, Canada, November 1-5 (2006).
5. Williams-Jones B, Ozdemir V: Challenges for corporate ethics in marketing genetic tests. J. Bus. Ethics (2007) [Epub ahead of print].
6. Ozdemir V, Kalow W, Tothfalusi L, Bertilsson L, Endrenyi L, Graham JE: Multigenic control of drug response and regulatory decision-making in pharmacogenomics: the need for an upper-bound estimate of genetic contributions. Curr. Pharmacogenomics 3, 53-71 (2005).
7. Motulsky AG: Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am. J. Hum. Genet. 58, 17-20 (1996).
8. Arranz MJ, de Leon J: Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry 12(8), 707-747 (2007).
9. Motulsky AG: From pharmacogenetics and ecogenetics to pharmacogenomics. Med. Secoli 14, 683-705 (2002).
10. Omenn GS, Motulsky AG: Ecogenetics: historical perspectives. In: Gene-Environment Interaction: Fundamentals of ecogenetics. Costa LG, Eaton DL (Eds). John Wiley & Sons, Chichester, UK. 7-16 (2006).
11. Bammler TK, Farin FM, Beyer RP: Tools of ecogenetics. In: Gene-Environment Interaction: Fundamentals of ecogenetics. Costa LG, Eaton DL (Eds). John Wiley & Sons, Chichester, UK, 17-50 (2006).
12. Hesketh J, Wybranska I, Dommels Y et al.: Nutrient-gene interactions in benefit-risk analysis. Br. J. Nutr. 95, 1232-1236 (2006).
13. de Leon J, Armstrong SC, Cozza KL: Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 47, 75-85 (2006).
14. de Leon J: AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert Rev. Mol. Diagnostics 6, 277-286 (2006).
15. Kaput J, Perlina A, Hatipolu B, Bartholomew A, Nikolsky Y: Nutrigenomics: concepts and applications to pharmacogenomics and clinical medicine. Pharmacogenomics 8, 369-390 (2007).
16. Davis CD: Nutrigenomics and the prevention of colon cancer. Pharmacogenomics 8, 121-124 (2007).
17. Subbiah MT: Nutrigenetics and nutraceuticals: the next wave riding on personalized medicine. Transl. Res. 149, 55-61 (2007).
18. Editorial (No authors listed): What's brewing in genetic testing. Nat. Genet. 32, 553-554 (2002).
19. Ozdemir V, Williams-Jones B, Graham JE et al.: Asymmetry in scientific method and limits to cross-disciplinary dialogue: towards a shared language and science policy in pharmacogenomics and human disease genetics. J. Investig. Med. 55, 130-141 (2007).
20. Ghosh D, Skinner MA, Laing WA: Pharmacogenomics and nutrigenomics: synergies and differences. Eur. J. Clin. Nutr. 61(5), 567-574 (2007).
21. Lampe JW: For debate: investment in nutrigenomics will advance the role of nutrition in public health. Cancer Epidemiol. Biomarkers Prev. 15, 2329-2330 (2006).
22. Bergmann MM, Bodzioch M, Bonet ML, Defoort C, Lietz G, Mathers JC: Bioethics in human nutrigenomics research: European Nutrigenomics Organisation workshop report. Br. J. Nutr. 95, 1024-1027 (2006).
23. Godard B, Marshall J, Laberge C, Knoppers BM: Strategies for consulting with the community: the cases of four large-scale genetic databases. Sci. Eng. Ethics 10(3), 457-477 (2004).
24. Godard B, Schmidtke J, Cassiman JJ, Ayme S: Data storage and DNA banking for biomedical research: informed consent, confidentiality, quality issues, ownership, return of benefits. A professional perspective. Eur. J. Hum. Genet. 11(Suppl. 2), S88-S122 (2003).
25. Hedgecoe A: The Politics of Personalised Medicine - Pharmacogenetics in the Clinic. Cambridge Studies in Society and the Life Sciences. Cambridge University Press, Cambridge, UK (2004).
26. Hopkins MM, Ibarreta D, Gaisser S et al.: Putting pharmacogenetics into practice. Nat. Biotechnol. 24, 403-410 (2006).
27. Denzin NK, Lincoln YS: The SAGE Handbook of Qualitative Research. 3rd Edition. Sage Publications, CA, USA, 1-1232 (2005).
28. Kaput J, Ordovas JM, Ferguson L et al.: The case for strategic international alliances to harness nutritional genomics for public and personal health. Br. J. Nutr. 94, 623-632 (2005).
29. Naito Y, Uchiyama K, Mizushima K et al.: Microarray profiling of gene expression patterns in glomerular cells of astaxanthin-treated diabetic mice: a nutrigenomic approach. Int. J. Mol. Med. 18, 685-695 (2006).
30. Bunger M, van den Bosch HM, van der Meijde J, Kersten S, Hooiveld GJ, Muller M: Genome-wide analysis of PPARα. Physiol. Genomics 30(2), 192-204 (2007).
31. Milner JA: Molecular targets for bioactive food components. J. Nutr. 134(9), S2492-S2498 (2004).
32. Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br. Med. J. 325(7374), 1202-1206 (2002).
33. Perla-Kajan J, Twardowski T, Jakubowski H: Mechanisms of homocysteine toxicity in humans. Amino Acids 32(4), 561-572 (2007).
34. Chwatko G, Boers GH, Strauss KA, Shih DM, Jakubowski H: Mutations in methylenetetrahydrofolate reductase or cystathionine β-syntase gene, or a high-methionine diet, increase homocysteine thiolactone levels in humans and mice. FASEB J. (2007) [Epub ahead of print].
35. Rozen R: Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb. Haemost. 78, 523-526 (1997).
36. Hughes LB, Beasley TM, Patel H et al.: Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 65, 1213-1218 (2006).
37. Ma J, Stampfer MJ, Giovannucci E et al.: Methylenetetrahydrofolate reductase polymorphism, dietary interactions and risk of colorectal cancer. Cancer Res. 57, 1098-1102 (1997).
38. Ma J, Stampfer MJ, Christensen B et al.: A polymorphism of the methionine synthase gene: association with plasma folate, vitamin B12, homocyst(e)ine, and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev. 8, 825-829 (1999).
39. Jacques PF, Bostom AG, Williams RR et al.: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93, 7-9 (1996).
40. Girelli D, Friso S, Trabetti E et al.: Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood 91, 4158-4163 (1998).
41. Fohr IP, Prinz-Langenohl R, Bronstrup A et al.: 5,10-methylenetetrahydrofolate reductase genotype determines the plasma homocysteine-lowering effect of supplementation with 5-methyltetrahydrofolate or folic acid in healthy young women. Am. J. Clin. Nutr. 75, 275-282 (2002).
42. Ashfield-Watt PA, Pullin CH, Whiting JM et al.: Methylenetetrahydrofolate reductase 677CT genotype modulates homocysteine responses to a folate-rich diet or a low-dose folic acid supplement: a randomized controlled trial. Am. J. Clin. Nutr. 76, 180-186 (2002).
43. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol. Genet. Metab. 64, 169-172 (1998).
44. van der Put NM, Gabreels F, Stevens EM et al.: A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am. J. Hum. Genet. 62, 1044-1051 (1998).
45. Gilbody S, Lewis S, Lightfoot T: Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am. J. Epidemiol. 165(1), 1-13 (2007).
46. Larsson SC, Giovannucci E, Wolk A: Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology 131(4), 1271-1283 (2006).
47. Friso S, Choi SW: Gene-nutrient interactions in one-carbon metabolism. Curr. Drug Metab. 6(1), 37-46 (2005).
48. Coppen A, Bolander-Gouaille C: Treatment of depression: time to consider folic acid and vitamin B12. J. Psychopharmacol. 19, 59-65 (2005).
49. Sharp L, Little J: Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am. J. Epidemiol. 159(5), 423-443 (2004).
50. Hedgecoe A: Education, ethics and knowledge deficits in clinical pharmacogenetics. Pharmacogenomics 8, 267-270 (2007).
51. Bammler T, Beyer RP, Bhattacharya S et al.: Standardizing global gene expression analysis between laboratories and across platforms. Nat. Methods 2, 351-356 (2005).
52. Corrigan OP, Williams-Jones B: Pharmacogenetics: the bioethical problem of DNA investment banking. Stud. Hist. Philos. Biol. Biomed. Sci. 37(3), 549-564 (2006).
53. Ozdemir V, Williams-Jones B, Glatt SJ et al.: Shifting emphasis from pharmacogenomics to theragnostics. Nat. Biotechnol. 28, 942-946 (2006).
54. Webster A, Martin P, Lewis G, Smart A: Integrating pharmacogenetics into society: in search of a model. Nat. Rev. Genet. 5, 663-669 (2004).
55. Sherrid P: Designer drugs. What's best for patients isn't always what's best for profits. US News World Report 131, 30-32 (2001).
56. Williams-Jones B, Corrigan OP: Rhetoric and hype: where's the 'ethics' in pharmacogenomics? Am. J. Pharmacogenomics 3, 375-383 (2003).
57. Smart A, Martin P, Parker M: Tailored medicine: whom will it fit? The ethics of patient and disease stratification. Bioethics 18, 322-342 (2004).
58. Sinha G: Drug companies accused of stalling tailored therapies. Nat. Medicine 12, 983 (2006).
59. Afman L, Muller M: Nutrigenomics: from molecular nutrition to prevention of disease. J. Am. Diet Assoc. 106, 569-576 (2006).
60. Rose N: The Politics of Life Itself: Biomedicine, Power, and Subjectivity in the Twenty-First Century. Princeton University Press, NJ, USA (2006).
61. Kalow W: Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. Pharmacogenomics J. 6, 162-165 (2006).
62. Rose N: Genomics. In: The Social Science Encyclopedia (3rd edition). Kuper A, Kuper J (Eds). Routledge, London, UK (2004).
63. Graham J, Ritchie K: Mild cognitive impairment: ethical considerations for nosological flexibility in human kinds. Philos. Psychiatr. Psychol. 13(2), 31-43 (2006).
64. Green J, Britten N: Qualitative research and evidence based medicine. Br. Med. J. 320, 114-116 (2000).
65. Barbour RS: Checklists for improving rigour in qualitative research: a case of the tail wagging the dog? Br. Med. J. 322, 1115-1117 (2001).
66. Sinuff T, Cook DJ, Giacomini M: How qualitative research can contribute to research in the intensive care unit. J. Crit. Care 22, 104-111 (2007).
67. Görman U: Ethical issues raised by personalized nutrition based on genetic information. Genes Nutrition 1, 13-22 (2006).
68. Beauchamp T, Childress J: Principles of Biomedical Ethics. Oxford University Press, NY, USA (1994).
69. Olson JA: Vitamin A. In: Handbook of Vitamins: Nutritional, Biochemical and Clinical aspects. Machlin LJ (Ed.). Marcel Dekker, NY, USA, 1-43 (1984).
70. Wang X, Qin X, Demirta H et al.: Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369(9576), 1876-1882 (2007).
71. Burke W, Khoury MJ, Stewart A, Zimmern RL; Bellagio Group: The path from genome-based research to population health: development of an international public-health genomics network. Genet. Med. 8(7), 451-458 (2006).
72. Castle D, Saner M, Cline C et al.: Convergent Biotechnologies Report. Program in Applied Ethics and Biotechnology. ORDC Fund. University of Guelph, Guelph, ON, Canada, 64-98 (2005).
73. Ries NM, Caulfield T: First pharmacogenomics, next nutrigenomics: genohype or genohealthy? Jurimetrics J. 46, 281-308 (2006).
74. Castle D, Cline C, Daar AS, Tsamis C, Singer PA: Science, Society and the Supermarket. The Opportunities and Challenges of Nutrigenomics. John Wiley & Sons, Hoboken, NJ, USA (2007).